|1.||Littlefield, Bruce A: 5 articles (06/2011 - 08/2004)|
|2.||Towle, Murray J: 3 articles (06/2011 - 08/2004)|
|3.||Shuster, Dale E: 3 articles (09/2010 - 06/2009)|
|4.||Ashworth, Simon: 3 articles (09/2010 - 06/2009)|
|5.||Fang, Fang: 3 articles (09/2010 - 06/2009)|
|6.||Awada, Ahmad: 2 articles (06/2014 - 09/2010)|
|7.||Newman, David J: 2 articles (01/2014 - 08/2007)|
|8.||Cheng, Hongsheng: 2 articles (03/2011 - 08/2004)|
|9.||Yu, Melvin J: 2 articles (03/2011 - 08/2004)|
|10.||Lewis, Bryan M: 2 articles (03/2011 - 02/2010)|
08/15/2004 - "E7389, a macrocyclic ketone analog of the marine natural product halichondrin B, currently is undergoing clinical trials for cancer. "
11/01/2015 - "Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial."
03/01/1990 - "In addition, several anti-tumor marine sponge constituents: halichondrin B, calyculin A, and mycalamides A and B, are briefly reviewed."
11/01/2015 - "The California Cancer Consortium completed a phase I trial of E7389 (eribulin mesylate), an analog of the marine natural product halichondrin B. "
02/16/2010 - "Eribulin mesylate (E7389), a synthetic analogue of the marine natural product halichondrin B, is in phase III clinical trials for the treatment of cancer. "
|2.||Breast Neoplasms (Breast Cancer)
06/01/2014 - "This synthetic analogue of halichondrin B, isolated from the marine sponge 'Halicondria Okaida', was responsible for prolonging overall survival of heavily pretreated metastatic breast cancer patients in a large Phase III trial. "
07/01/2008 - "Eribulin (E7389), a synthetic analogue of halichondrin B in phase III clinical trials for breast cancer, binds to tubulin and microtubules. "
06/01/2015 - "Eribulin mesylate (eribulin), an analogue of the marine natural product halichondrin B, is a microtubule-depolymerizing drug that has utility in the treatment of patients with breast cancer. "
05/01/2012 - "Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer."
06/01/2011 - "Eribulin mesylate, a novel microtubule-targeting analogue of the marine natural product halichondrin B, has recently shown antineoplastic activity, with relatively low incidence and severity of neuropathy, in metastatic breast cancer patients. "
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
|4.||Ovarian Neoplasms (Ovarian Cancer)
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|1.||2- (3- amino- 2- hydroxypropyl)hexacosahydro- 3- methoxy- 26- methyl- 20,27- bis(methylene)11,15- 18,21- 24,28- triepoxy- 7,9- ethano- 12,15- methano- 9H,15H- furo(3,2- i)furo(2',3'- 5,6)pyrano(4,3- b)(1,4)dioxacyclopentacosin- 5- (4H)- one